Sign in
Taking people in United StatesPhase 3

Tests setmelanotide against placebo in people with congenital hypothalamic obesity

Tests setmelanotide injections against placebo in patients aged 4 years and older.

Key facts

Who runs it
Rhythm Pharmaceuticals, Inc.
Where
Aurora, Birmingham, Boston, Chicago, New York, Philadelphia, Saint Paul, and Seattle, United StatesSee the 8 sitesAlso in 1 other country, 3 sites
Trial code
Registry title
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Status
Recruiting
Phase
Phase 3
People taking part
39 people, planned
Started
23 Sept 2025
Expected to end
13 Mar 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Setmelanotide
  • Placebo
Record updated
12 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 4 and older with obesity caused by a congenital hypothalamic or pituitary condition. Participants take a daily injection of setmelanotide or placebo for up to 26 weeks.

Age
4 years and older.
Sex
All sexes can join.
Disease stage
A diagnosis of multiple pituitary hormone deficiency, septo-optic dysplasia, optic nerve hypoplasia, childhood-onset combined pituitary hormone deficiency, or pituitary stalk interruption syndrome with at least one pituitary deficiency. Weight gain linked to the hypothalamic injury. BMI of 30 kg/m2 or more for adults aged 18 and older, or BMI at or above the 95th percentile for age and sex for ages 4 to under 18.
Earlier treatment
No earlier trial with setmelanotide and no earlier exposure to it. No bariatric surgery or procedure in the last 2 years. No trial drug or device in the last 3 months. Hormone replacement therapy dose must be stable for at least 2 months before screening.

Main reasons for not taking part

  • Prader-Willi syndrome or ROHHADNET
  • Weight loss over 2% in the last 3 months (adults), or BMI drop over 2% (ages 4 to under 18)
  • Severe psychiatric disorder, or any suicidal thoughts, attempt or behavior
  • Skin cancer or melanoma, or close family history of it
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Diagnosis of multiple pituitary hormone deficiency (MPHD), or septo-optic dysplasia (SOD), or optic nerve hypoplasia (ONH), or Childhood-onset combined pituitary hormone deficiency (CPHD), or Pituitary Stalk Interruption Syndrome (PSIS) with at least one pituitary deficiency AND a body mass index (BMI) of ≥30 kg/m2 for patients ≥18 years of age, or BMI ≥95th percentile for age and sex for patients 4 to <18 years
  • Age 4 years and older
  • Weight gain associated with the hypothalamic injury and a BMI of ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients 4 to <18 years of age
  • Agree to use a highly effective form of contraception throughout the study and for 90 days after the study

Who cannot take part

  • Weight loss >2% in the previous 3 months for patients aged ≥18 years or >2% reduction in BMI for patients aged 4 to <18 years
  • Bariatric surgery or procedure within last 2 years
  • Participation in any clinical trial with an investigational drug/device within 3 months prior to the first trial dose
  • Previously enrolled in a clinical trial involving setmelanotide or any previous exposure to setmelanotide
  • If receiving hormone replacement therapy, dose has remained stable for at least 2 months before Screening; Other protocol defined Inclusion/Exclusion criteria may apply
  • Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET)
  • Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior
  • Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease
  • History or close family history of skin cancer or melanoma
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Inability to comply with once daily (QD) injection regimen
  • If female, pregnant and/or breastfeeding

Where in United States

Also in 1 other country, 3 sites

  • Children's Hospital ColoradoAurora, United StatesContact: Rhythm Clinical TrialsTaking people
  • University of AlabamaBirmingham, United StatesContact: Rhythm Clinical TrialsTaking people
  • Boston Children's HospitalBoston, United StatesContact: Rhythm Clinical TrialsTaking people
  • Lurie Children's HospitalChicago, United StatesContact: Rhythm Clinical TrialsTaking people
  • Columbia University Irving Medical CenterNew York, United StatesContact: Rhythm Clinical TrialsTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Rhythm Clinical TrialsTaking people
  • Children's MinnesotaSaint Paul, United StatesContact: Rhythm Clinical TrialsTaking people
  • Seattle Children's Research InstituteSeattle, United StatesContact: Rhythm Clinical TrialsTaking people

About the trial

What the trial wants to find out

This is a sub-study of Study RM-493-040 (NCT05774756).

Read full original descriptionShow less

The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how well setmelanotide works and how safe it is, patients with cHO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 26 weeks on a therapeutic regimen.

The 2 groups in the trial

  • SetemelanotideTreatment being tested

    Randomized 2:1 (Setmelanotide: Placebo)

    Treatment: Setmelanotide

  • PlaceboPlacebo, for comparison

    Randomized 2:1 (Setmelanotide: Placebo)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity
Plain-language title
Tests setmelanotide against placebo in people with congenital hypothalamic obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 February 2026